The emerging field of ecogenetics.

Area of Science:

• Ecogenetics
• Pharmacogenetics
• Toxicology

Background:

• Individual susceptibility to drugs and chemicals is influenced by genetic variations in biotransformation enzymes and target proteins.
• Ecogenetics, an evolution of pharmacogenetics, explores genetic polymorphisms as risk factors for diseases associated with toxic chemical exposure.

Purpose of the Study:

• To investigate the role of genetic polymorphisms in susceptibility to environmental chemicals and diseases.
• To discuss specific polymorphisms (aldehyde dehydrogenase, delta-aminolevulinic acid dehydratase) in relation to alcohol and lead toxicity.
• To examine the implications of genetic polymorphisms in neurodegenerative diseases like Parkinson's disease.

Main Methods:

• Review and discussion of existing literature on genetic polymorphisms.
• Focus on specific enzyme polymorphisms and their toxicological relevance.
• Exploration of the functional significance and interactions of genetic polymorphisms.

Main Results:

• Genetic polymorphisms in enzymes like aldehyde dehydrogenase and delta-aminolevulinic acid dehydratase are linked to alcohol and lead toxicity, respectively.
• Genetic polymorphisms play a role in the risk of developing neurodegenerative diseases, including Parkinson's disease.
• The functional significance, interactions, and ethical considerations of genetic polymorphisms are important areas of study.

Conclusions:

• Genetic polymorphisms are critical determinants of individual susceptibility to toxic chemicals and drug responses.
• Ecogenetics provides a framework for understanding environmentally-induced diseases at a genetic level.
• Further research into genetic polymorphisms, their interactions, and associated ethical issues is warranted.